Answers are grounded in this paper and cite their sources.
SOX 9 is a master transcription factor that regulates development and stem cell programs. However, its potential oncogenic activity and regulatory mechanisms that control SOX 9 protein stability are poorly understood. Here, we show that SOX 9 is a substrate of FBW 7, a tumor suppressor, and a SCF ( SKP 1/ CUL 1/F‐box)‐type ubiquitin ligase. FBW 7 recognizes a conserved degron surrounding threonine 236 (T236) in SOX 9 that is phosphorylated by GSK 3 kinase and consequently degraded by SCF FBW 7α . Failure to degrade SOX 9 promotes migration, metastasis, and treatment resistance in medulloblastoma, one of the most common childhood brain tumors. FBW 7 is either mutated or downregulated in medulloblastoma, and in cases where FBW 7 mRNA levels are low, SOX 9 protein is significantly elevated and this phenotype is associated with metastasis at diagnosis and poor patient outcome. Transcriptional profiling of medulloblastoma cells expressing a degradation‐resistant SOX 9 mutant reveals activation of pro‐metastatic genes and genes linked to cisplatin resistance. Finally, we show that pharmacological inhibition of PI 3K/ AKT / mTOR pathway activity destabilizes SOX 9 in a GSK 3/ FBW 7‐dependent manner, rendering medulloblastoma cells sensitive to cytostatic treatment.
No takes yet. Share an insight, caveat, or question.
Rahmanto et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: